Scott Rottinghaus
Chief Medical Officer
Replay available
Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) Q1 2024 earnings conference call, held 2024-02-07. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Paul Mellott
Chief Financial Officer
Jay Lulli
President and Chief Executive Officer
Brian Scorny
Analyst at Beard ( represented by Charlie)
Eric Joseph
Analyst at JP Morgan
Roy Buchanan
Analyst at JMP
Ed Arce
Analyst at HC Wainwright (question asked via Thomas)
Jennifer Vera
Investor Relations
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Enanta Pharmaceuticals, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.069 -- 00:00:05.311 Good afternoon, and welcome to Enanta Pharmaceuticals Fiscal First Quarter 00:00:05.311 -- 00:00:09.833 Financial Results Conference Call. At this time, all participants are on a listen-only 00:00:09.833 -- 00:00:15.555 mode. There will be a question-and-answer session at the end of the prepared remarks. 00:00:15.555 -- 00:00:18.136 Please be advised that this call is being recorded. 00:00:18.136 -- 00:00:22.138 I would now like to turn the call over to Jennifer Vera, Investor Relations. 00:00:22.138 -- 00:00:24.598 Please go ahead. 00:00:27.250 -- 00:00:31.433 Thank you, Operator, and thanks to everyone for joining us this afternoon. 00:00:31.433 -- 00:00:36.156 The news release with our fiscal first quarter financial results was issued this afternoon 00:00:36.156 -- 00:00:40.579 and is available on our website. Making remarks on today's call are Dr. 00:00:40.579 -- 00:00:45.323 Jay Lulli, President and Chief Executive Officer, and Paul Mellott, our Chief Financial 00:00:45.323 -- 00:00:49.686 Officer. Dr. Scott Rottinghaus, our Chief Medical Officer, and Dr. 00:00:49.686 -- 00:00:54.849 Tara Kiefer, our Chief Product Strategy Officer, will be available during the Q&A 00:00:54.849 -- 00:00:56.994 portion of this call. 00:00:56.994 -- 00:01:00.837 Before we begin with our formal remarks, we want to remind you that we will be making 00:01:00.837 -- 00:01:05.440 forward-looking statements, which may include our plans and expectations with respect 00:01:05.440 -- 00:01:10.123 to our research and development pipeline and financial projections, all of which involve 00:01:10.123 -- 00:01:15.627 certain assumptions and risks beyond our control that could cause our actual developments 00:01:15.627 -- 00:01:19.110 and results to differ mate...